Navigation Links
New England Peptide, Inc. and Cambridge Isotope Laboratories, Inc. Announce Quantitative Proteomics Manufacturing Collaboration

Gardner, MA (PRWEB) July 16, 2013

New England Peptide, Inc. (NEP) and Cambridge Isotope Laboratories, Inc. (CIL) announced a joint manufacturing and marketing agreement of pre-loaded resins for the synthesis of peptide stable isotope standards (SIS).

Under the terms of the agreement CIL will provide high purity stable isotope amino acids to NEP and NEP will load the isotopologues onto peptide synthesis resins, perform quality control on the resins, and redistribute to CIL. Both companies have agreed to co-market and sell the pre-loaded resins to peptide synthesis laboratories worldwide.

"We saw this collaboration as an important way to facilitate the synthesis of peptide stable isotope standards (SIS). This product will increase the availability and decrease the cost of SIS peptides, which will help the quantitative proteomics field grow", commented Sam Massoni, President and CEO of New England Peptide, Inc.

The gold standard for MS-based quantitative methods is to use a mass-shifted, stable-isotope-labeled peptide standard spiked into the sample of interest, which then allows quantification from a simple ratio of the labeled peak height to the unlabeled. This collaboration is further evidence of NEP and CIL’s commitment to the field.

"We were the first company to manufacture protected stable isotope labeled amino acids at 99% isotopic enrichment. NEP was one of the reasons we have been expanding our production of these 99% enriched reagents. NEP requested the highest quality reagents to meet the increased demand of SIS peptides, and we met that need. This collaboration is a natural fit for both companies and adds value to both product lines", commented Maureen Duffy, VP of Sales and Marketing at Cambridge Isotope Laboratories, Inc.

NEP is one of the premier peptide synthesis companies.

About New England Peptide (NEP)

New England Peptide, founded in 1998, designs and manufactures peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, MA., the company’s chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications. NEP is a worldwide leader in providing SIS peptides for the quantitative proteomics field. More information on NEP can be found at

About Cambridge Isotope Laboratories, Inc. (CIL)

CIL is the world’s leading manufacturer of stable isotope labeled reagents for research applications in proteomics, genomics, molecular biology, metabolic research, clinical and diagnostic research and ultra trace environmental analysis. For over 30 years CIL has provided over 15,000 different research compounds to its base of over 35,000 medical, pharmaceutical, academic and government customers.

CIL corporate headquarters are located in Tewksbury, MA. More information on CIL can be found at

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Rates of infection in intensive care units in England show impressive fall
2. University of New England and Partners Celebrate Opening of Portland Community Health Center at Riverton June 20 for Underserved Populations
3. National HealthCare Associates Acquires Five New Centers throughout New England
4. University of New England Graduates First Class with Pharmacy Doctoral Degrees
5. Luke Cooper, CEO, Asurvest, Inc., Nominated For The New England Patriots Myra Kraft Community MVP Award
6. Moderate Red Tide Expected in New England This Summer
7. Hospital remains most common place of death for cancer patients in England
8. Cosmetic Enhancement Center of New England Now Has Satellite Locations
9. New Englanders Without IVF Coverage Have a More Affordable Way to Seek Help Through the WINFertility® Treatment Program
10. Just a drop? Alcohol consumption much higher than reported in England
11. Care New England Executive selected for prestigious program
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, ... the womb. "My last baby had high blood pressure due to loud noises," she ... protect their babies from noise pollution as well as radio waves and microwaves." , ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... automated breast density assessment and enterprise analytics solutions, here at the 101st ... (South Hall booth #2377). Volpara’s quantitative breast imaging tools enable personalized measurements ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... – Kreithen”), one of the leading plastic surgery practices in Florida, is proud ... chosen to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson ...
(Date:11/30/2015)... Morton Grove, IL (PRWEB) , ... November 30, 2015 , ... ... milestone for an emerging pharmaceutical company. Because it is so important to this key ... titled “Success Factors in your IND Filing” on December 4th at 11am EST. , ...
(Date:11/30/2015)... ... 30, 2015 , ... Healthjump, Inc. announced that it has ... consulting, development and support company. The purchase will expand the capability to serve ... extend the services currently provided by Healthjump. , Through this purchase, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... BOSTON , Nov. 30, 2015  Kevin ... of Sensium Healthcare, a global pioneer in wireless ... Boston, MA , Mr. Smith ... of Sensium,s global commercial strategy.  He will also ... universities, to build clinical evidence for SensiumVitals, the ...
(Date:11/30/2015)... , Nov. 30, 2015  The fee-for-service ... in U.S. medical imaging is on its ... accountable care payer-provider contracts are set to ... their wake, alter provider-vendor relationships. The shift ... push forward new purchasing frameworks in the ...
(Date:11/30/2015)... WOODCLIFF LAKE, N.J. and SAN ... Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... (FDA) has accepted for filing the New Drug Application ... approved, the extended release formulation will offer patients a ... ® ) is currently approved as ...
Breaking Medicine Technology: